Datopotamab deruxtecan
- Generic Name
- Datopotamab deruxtecan
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2238831-60-0
- Unique Ingredient Identifier
- GD2OWY1DTK
- Background
Datopotamab deruxtecan is under investigation in clinical trial NCT04656652 (Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)).
- Associated Conditions
- -
- Associated Therapies
- -
Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients with Active Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 20
- Registration Number
- NCT06676917
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT06564844
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ana C Garrido-Castro, MD
- Target Recruit Count
- 357
- Registration Number
- NCT06533826
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 675
- Registration Number
- NCT06357533
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 582
- Registration Number
- NCT06350097
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT06279728
- Locations
- 🇪🇸
Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain
🇪🇸Hospital Universitario Miguel Servet, Zaragoza, Spain
🇨ðŸ‡Hopitaux Universitaires Genève (HUG), Geneva, Switzerland
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Sarah Sammons, MD
- Target Recruit Count
- 58
- Registration Number
- NCT06176261
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 20
- Registration Number
- NCT05866432
- Locations
- 🇦🇹
AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology, Vienna, Austria
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1350
- Registration Number
- NCT05687266
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1170
- Registration Number
- NCT05555732
- Locations
- 🇺🇸
Florida Cancer Specialists-North, Saint Petersburg, Florida, United States
🇯🇵Osaka International Cancer Institute, Osaka, Japan
🇺🇸Southern Cancer Center Pc, Daphne, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.